Muscle does not wait for old age to start failing. It begins losing ground decades before most people notice, quietly trading strength for scar tissue and fat, and shedding the fast-twitch fibers that let a body react quickly. A team at Kyushu University's Faculty of Agriculture believes it has found a way to slow that slide, and the mechanism they describe reads less like a supplement pitch and more like a repair job on the body's own machinery.

The findings, published July 24, 2026, in the journal Scientific Reports, center on a sulfur-based molecule called lipoic acid trisulfide, or LASSS. According to the research team led by Professor Ryuichi Tatsumi, this compound doesn't just protect a critical muscle-repair protein from age-related damage, it appears to upgrade the protein's function beyond its original baseline.

The protein that goes quiet with age

The protein in question is hepatocyte growth factor, or HGF, and it functions like an alarm clock for muscle stem cells. In healthy tissue, HGF sits dormant within the connective network surrounding muscle fibers. When that tissue is injured or put under mechanical stress, HGF releases and binds to c-met receptors on satellite cells, the resident stem cells responsible for muscle maintenance and repair. That binding wakes the satellite cells up, prompting them to multiply, specialize, and rebuild damaged fiber.

The Kyushu team's earlier work had already identified the problem that breaks this system down with age: a chemical modification called nitration, which attaches a nitro group to two specific sites on HGF, labeled Y198 and Y250. Those sites happen to be exactly where HGF needs to grip the c-met receptor. Once nitrated, the protein can no longer dock properly, described by the researchers as a rusted key that no longer fits its lock. That failure to bind is believed to be a root driver of age-related muscle wasting and slower regeneration after injury.

Testing two candidate molecules

To address the nitration problem, the researchers tested two sulfur-containing trisulfide compounds known for strong antioxidant activity: glutathione trisulfide, or GSSSG, and lipoic acid trisulfide, or LASSS. Both molecules reduced nitration at the Y198 and Y250 sites in initial experiments, but neither fully restored HGF's ability to bind its receptor at standard concentrations.

The breakthrough came when the team raised the molar ratio of HGF to trisulfide from 1:4000 to 1:8000. At that higher concentration, LASSS produced what the researchers describe as an unexpected result: rather than simply preventing further damage, it appears to reshape HGF's structure into a more effective form entirely.

Building what the team calls "Super HGF"

At the 1:8000 ratio, HGF treated with LASSS showed binding affinity for the c-met receptor more than double that of native, unnitrated HGF, while also becoming highly resistant to future nitration. The team refers to this enhanced version informally as Super HGF. Notably, GSSSG did not replicate this effect, restoring some resistance to nitration but failing to meaningfully improve receptor binding, which suggests the benefit is specific to LASSS's particular sulfur chemistry rather than a general property of trisulfides.

That specificity matters for anyone hoping this becomes a therapy rather than a lab curiosity. It means the effect isn't simply "more antioxidant is better," it is a precise structural interaction between one molecule and one protein, the kind of finding that tends to translate more reliably into a drug candidate.

Confirming the effect inside a living body

Cell-culture results are one thing; living tissue is another. To test whether the effect held up in vivo, the researchers used a tail-suspension mouse model, a standard method for simulating disuse muscle atrophy similar to what happens during prolonged bed rest or extended immobility. Mice pretreated with LASSS before the procedure showed significantly lower HGF nitration levels than untreated mice, while GSSSG again failed to produce a measurable protective effect. That result is what pushes this from a molecular observation toward a genuine therapeutic candidate, since it shows the compound retains its protective behavior in an actual physiological system, not just in a test tube.

What this could mean beyond the lab

Because HGF signaling is highly conserved across mammals, the research team believes the approach could extend well past humans, potentially applying to age-related muscle loss in companion animals such as dogs and cats as well. The immediate clinical target is sarcopenia, the progressive loss of muscle mass and strength that affects a large share of older adults and is linked to falls, loss of independence, and higher mortality risk. A compound that keeps HGF functional, rather than merely slowing its decline, could in principle give clinicians a genuinely new lever against a condition that currently has few effective drug treatments.

The researchers are careful to frame this as an early-stage discovery rather than a finished therapy; LASSS has not been tested in human trials, and translating a cell and mouse-model finding into an approved treatment typically takes years. Still, the specificity of the mechanism, one molecule precisely reshaping one protein's function rather than offering a vague antioxidant boost, is the kind of detail that tends to hold up as research moves toward clinical testing.

---

*Sources cited in this article include the peer-reviewed study published July 24, 2026 in Scientific Reports, and reporting from ScienceDaily, EurekAlert, MedicalXpress, Neuroscience News, and Kyushu University's own research communications. All figures reflect reporting available as of July 25, 2026.*